HK Stock Market Move | Jiangsu Hengrui Pharmaceuticals (01276) rose by more than 6% during trading. Recently, the innovative drug Ibrutinib has added new indications and achieved fruitful results in internationalization and going global.

Jiangsu Hengrui Pharmaceuticals (01276) rose more than 6% in midday trading, up 3.54% to HK$59.9 as of press time, with a trading volume of HK$136 million. On the news front, Jiangsu Hengrui Pharmaceuticals' independently developed PD-L1 inhibitor Aiyirui (atezolizumab injection) received approval for new indications from the National Medical Products Administration. It is used in combination with platinum-based chemotherapy as neoadjuvant therapy, followed by continued monotherapy with this product as adjuvant therapy, for the treatment of operable stage II, IIIA, and IIIB adult non-small cell lung cancer (NSCLC) patients without known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements. Southwest believes that this approval complements the company's product portfolio in the field of lung cancer, covering the full treatment course of existing late-stage indications, and is also expected to synergize with the company's self-developed ADC and other multi-technology platforms to release incremental value in the perioperative and metastatic setting. Guotou Securities previously pointed out that since 2023, Jiangsu Hengrui Pharmaceuticals has made significant achievements in overseas BD collaboration for innovative drugs, reaching agreements with multiple MNCs and biotech companies with a potential total transaction amount exceeding $30 billion. The company's overseas BD efforts continue to deliver, with multiple varieties beyond cooperation milestones potentially receiving sales royalties in overseas markets. The bank believes that the company's overseas market valuation is expected to be reshaped as the internationalization strategy progresses smoothly, and the subsequent progress is worth looking forward to.